- Home
- ACRS vs CGO Comparison
ACRS vs CGO Comparison
Compare ACRS & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CGO
- Stock Information
- Founded
- ACRS 2012
- CGO 2004
- Country
- ACRS United States
- CGO United States
- Employees
- ACRS N/A
- CGO N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CGO Investment Managers
- Sector
- ACRS Health Care
- CGO Finance
- Exchange
- ACRS Nasdaq
- CGO Nasdaq
- Market Cap
- ACRS 132.0M
- CGO 117.5M
- IPO Year
- ACRS 2015
- CGO N/A
- Fundamental
- Price
- ACRS $4.32
- CGO $11.89
- Analyst Decision
- ACRS Buy
- CGO
- Analyst Count
- ACRS 6
- CGO 0
- Target Price
- ACRS $7.20
- CGO N/A
- AVG Volume (30 Days)
- ACRS 6.0M
- CGO 34.7K
- Earning Date
- ACRS 11-06-2024
- CGO 01-01-0001
- Dividend Yield
- ACRS N/A
- CGO 9.25%
- EPS Growth
- ACRS N/A
- CGO N/A
- EPS
- ACRS N/A
- CGO N/A
- Revenue
- ACRS $27,079,000.00
- CGO N/A
- Revenue This Year
- ACRS N/A
- CGO N/A
- Revenue Next Year
- ACRS N/A
- CGO N/A
- P/E Ratio
- ACRS N/A
- CGO N/A
- Revenue Growth
- ACRS 26.35
- CGO N/A
- 52 Week Low
- ACRS $0.77
- CGO $7.90
- 52 Week High
- ACRS $5.17
- CGO $10.93
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- CGO 52.06
- Support Level
- ACRS $3.67
- CGO $11.43
- Resistance Level
- ACRS $5.17
- CGO $11.84
- Average True Range (ATR)
- ACRS 0.47
- CGO 0.24
- MACD
- ACRS 0.20
- CGO 0.01
- Stochastic Oscillator
- ACRS 72.93
- CGO 80.77
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.